$ALEC

Berkley Neil Lindsay sold $38K of ALEC

Berkley Neil Lindsay (CFO & Chief Business Officer) sold 19,360 shares of Alector, Inc. (ALEC) at $1.97 on 2026-06-02.

Original reporting
SEC EDGAR · Berkley Neil Lindsay
Published Jun 3, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALEC
Neutral
medium confidence
Mentioned
$ALEC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALECNeutralLow
01

Why it matters

The disclosure may slightly influence short-term sentiment, but it does not introduce new operational or clinical information about Alector.

02

Market read

Traders may monitor for subsequent insider buying/selling patterns, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

Insider sales often occur for tax/liquidity reasons; without follow-on purchases or broader insider activity, the signal is weak.

Relevance 6/10Novelty 6/10Timing: Filed/visible after-hours on 2026-06-03; sale occurred 2026-06-02.

Background

This is an SEC Form 4 insider transaction disclosure for Alector, Inc. (ALEC).

Company-level read

Ticker impact

$ALECNeutralMedium confidence
Context

Alector CFO/Chief Business Officer Berkley Neil Lindsay sold 19,360 shares in an open-market transaction disclosed on Form 4.

Expected impact

Likely limited and short-lived; any impact would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing provides a discrete sale size and price but no accompanying company-specific catalyst (earnings, trial, deal, or guidance).

Market effects

Minimal; single-company insider transaction without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Because the sale is not disclosed as 10b5-1, it could be routine diversification rather than a bearish view on fundamentals.

Key entities

  • Alector, Inc.

    Subject of the Form 4 insider sale by its CFO & Chief Business Officer.

  • Berkley Neil Lindsay

    CFO & Chief Business Officer who sold 19,360 shares at $1.9742 on 2026-06-02.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

MedAI 8/10

Genentech pays Alector $100m for Parkinson drug

Genentech paid Alector $100m upfront for global rights to AL050, a Parkinson's drug. Alector may receive up to $1.17b in milestones. AL050 targets GCase deficiency, a factor in Parkinson's. The deal extends Alector's cash runway to 2029, supporting other Alzheimer's and Parkinson's programs.

HighAI 9/10

Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion

Roche will pay up to $1.27 billion to license Alector's experimental Parkinson's therapy, AL050. The deal includes a $100 million upfront payment and potential milestone payments. Alector's shares surged 72% in premarket trading. Roche's Genentech unit will handle development and commercialization, with Alector eligible for royalties.

$ALECHigh

Alector (ALEC) Shares Jump 22% on Genentech Licensing Deal for A

Alector Inc (ALEC) shares rose 22% after announcing a licensing deal with Genentech for its AL050 program. The deal includes a $100M upfront payment and potential milestone payments up to $1.17B. Alector's P/S ratio is 17.46, higher than historical and industry averages, reflecting growth expectations. The company's GF Score is 31/100, indicating weak fundamentals but some momentum.